Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia
Rafal Pawlinski,Brian Pedersen,Gernot Schabbauer,Michael Tencati,Todd Holscher,William A. Boisvert,Patricia Andrade-Gordon,Rolf Dario Frank,Nigel Mackman +8 more
TLDR
Data demonstrate that hematopoietic cells are the major pathologic site of TF expression during endotoxemia and suggest that multiple protease-activated receptors mediate crosstalk between coagulation and inflammation.About:
This article is published in Blood.The article was published on 2004-02-15 and is currently open access. It has received 279 citations till now. The article focuses on the topics: Thrombin & Tissue factor.read more
Citations
More filters
Journal ArticleDOI
Protease-activated receptors in hemostasis, thrombosis and vascular biology.
TL;DR: Roles for PARs in blood vessel formation and other processes during embryonic development are emerging, and whether these reflect new roles for the coagulation cascade and/or PAR signaling to other proteases remains to be explored.
Journal ArticleDOI
New fundamentals in hemostasis
TL;DR: This review summarizes new concepts of activation of proteases that regulate coagulation and anticoagulation, to give rise to transient thrombin generation and fibrin clot formation and speculates on the (patho)physiological roles of intra- and extravascular receptors that operate in response to these proteases.
Journal ArticleDOI
Role of the Extrinsic Pathway of Blood Coagulation in Hemostasis and Thrombosis
TL;DR: Understanding how the extrinsic pathway of blood coagulation contributes to hemostasis and thrombosis may lead to the development of safe and effective hemostatic agents and antithrombotic drugs.
Journal ArticleDOI
Inflammation, endothelium, and coagulation in sepsis
TL;DR: The relationship between endothelium and coagulation in sepsis is tight and that further research is needed, for example, to better understand the role of activated PC signaling via PAR‐1, the roles of the endothelial PC receptor herein, and therole of the glycocalyx.
Journal ArticleDOI
Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications.
TL;DR: Tissue Factor (TF) is the key initiator of the coagulation cascade; it binds factor VIIa resulting in activation of factor IX and factor X, ultimately leading to fibrin formation as mentioned in this paper.
References
More filters
Journal ArticleDOI
Efficacy and safety of recombinant human activated protein C for severe sepsis.
G Ordon R. B Ernard,J Ean L Ouis V Incent,L Aterre,S Teven P. L A R Osa,J Ean,A Ngel L Opez,J Ay S. S Teingrub,G Ary E. G Arber,J Effrey,D. H Elterbrand,E. W Esley E Ly,C Harles J. F Isher,S Evere S Epsis,S Tudy G Roup +13 more
TL;DR: This phase 3 trial assessed whether treatment with drotrecogin alfa activated reduced the rate of death from any cause among patients with severe sepsis.
Journal ArticleDOI
Thrombin signalling and protease-activated receptors
TL;DR: Roles for PARs are beginning to emerge in haemostasis and thrombosis, inflammation, and perhaps even blood vessel development.
Journal ArticleDOI
Disseminated Intravascular Coagulation
Marcel Levi,Ten Cate H +1 more
TL;DR: Bleeding may be the presenting symptom in a patient with disseminated intravascular coagulation, a factor that can complicate decisions about treatment, and the use and subsequent depletion of platelets and coagulating proteins resulting from the ongoing coagulations may induce severe bleeding.
Journal ArticleDOI
Pathogenetic Mechanisms of Septic Shock
TL;DR: One of the most frequent and serious problems confronting clinicians is the management of a serious infection and the systemic response to infection, a syndrome termed sepsis, when this syndrome results in hypotension and organ dysfunction, called septic shock.
Journal ArticleDOI
Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.
Edward Abraham,Konrad Reinhart,Steven M. Opal,Ignace Demeyer,Christopher J. Doig,Angel López Rodriguez,Richard Beale,Petr Svoboda,Pierre-François Laterre,Stuart Simon,Bruce Light,Herbert Spapen,Judy Stone,Allan Seibert,Claus Peckelsen,Cathy De Deyne,Russell Postier,Ville Pettilä,Charles L. Sprung,Antonio Artigas,Sandra Percell,Vincent Shu,Christian Zwingelstein,Jeffrey Tobias,Lona Poole,James C. Stolzenbach,Abla A. Creasey +26 more
TL;DR: Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR and tifACogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.
Related Papers (5)
Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.
Edward Abraham,Konrad Reinhart,Steven M. Opal,Ignace Demeyer,Christopher J. Doig,Angel López Rodriguez,Richard Beale,Petr Svoboda,Pierre-François Laterre,Stuart Simon,Bruce Light,Herbert Spapen,Judy Stone,Allan Seibert,Claus Peckelsen,Cathy De Deyne,Russell Postier,Ville Pettilä,Charles L. Sprung,Antonio Artigas,Sandra Percell,Vincent Shu,Christian Zwingelstein,Jeffrey Tobias,Lona Poole,James C. Stolzenbach,Abla A. Creasey +26 more